Krilogy Financial LLC Buys Shares of 10,500 IQVIA Holdings Inc. (NYSE:IQV)

Krilogy Financial LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 10,500 shares of the medical research company’s stock, valued at approximately $1,851,000.

Other large investors also recently made changes to their positions in the company. American National Bank & Trust bought a new position in shares of IQVIA during the 1st quarter valued at about $26,000. ST Germain D J Co. Inc. boosted its position in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA during the 4th quarter valued at about $39,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA during the 4th quarter valued at about $44,000. Finally, Zions Bancorporation N.A. boosted its position in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 85 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of several research reports. HSBC lowered shares of IQVIA from a “buy” rating to a “hold” rating and reduced their price objective for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Mizuho decreased their target price on shares of IQVIA from $210.00 to $190.00 and set an “outperform” rating for the company in a report on Thursday, May 15th. Barclays decreased their target price on shares of IQVIA from $170.00 to $165.00 and set an “equal weight” rating for the company in a report on Wednesday, May 7th. Truist Financial decreased their target price on shares of IQVIA from $263.00 to $216.00 and set a “buy” rating for the company in a report on Thursday, April 10th. Finally, Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Eight investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $226.32.

IQVIA Stock Performance

IQV stock opened at $156.65 on Friday. The stock has a market cap of $27.10 billion, a P/E ratio of 20.89, a P/E/G ratio of 1.99 and a beta of 1.28. The firm has a 50 day simple moving average of $147.59 and a 200 day simple moving average of $177.68. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter last year, the firm earned $2.54 earnings per share. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.